Skip to main content

Table 2 Patient-reported change in EORTC QLQ-C30 scores from baseline to week 4 in the OXN-CR and OX-CR groups (FAS)

From: Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

Variable

Score at baseline

Score at week 4

Score change from baseline to week 4

OXN-CR (n = 58)

OX-CR (n = 59)

OXN-CR (n = 36)a

OX-CR (n = 31)a

OXN-CR (n = 36)a

P value

OX-CR (n = 31)a

P value

Global health status

3.74 ± 1.19

3.49 ± 1.34

3.88 ± 1.38

3.65 ± 1.21

−0.01 ± 1.34

0.951

−0.16 ± 1.50

0.554

Functional scales

 Physical functioning

1.89 ± 0.56

2.23 ± 0.67

2.14 ± 0.70

2.21 ± 0.67

0.29 ± 0.54

0.002

0.09 ± 0.54

0.360

 Role functioning

1.85 ± 0.77

2.40 ± 1.03

2.21 ± 0.86

2.42 ± 0.99

0.44 ± 0.87

0.002

0.24 ± 0.88

0.126

 Emotional functioning

1.72 ± 0.58

1.96 ± 0.65

1.86 ± 0.59

2.06 ± 0.84

0.15 ± 0.48

0.073

0.19 ± 0.69

0.241

 Cognitive functioning

1.53 ± 0.55

1.85 ± 0.63

1.92 ± 0.65

1.95 ± 0.85

0.35 ± 0.77

0.011

0.13 ± 0.59

0.280

 Social functioning

1.92 ± 0.70

2.12 ± 0.96

2.03 ± 0.70

2.15 ± 0.94

0.21 ± 0.85

0.200

0.11 ± 0.72

0.512

Symptoms scales/items

 Fatigue

2.13 ± 0.68

2.41 ± 0.76

2.44 ± 0.70

2.42 ± 0.80

0.35 ± 0.68

0.004

0.16 ± 0.74

0.234

 Nausea and vomiting

1.49 ± 0.73

1.63 ± 0.67

1.67 ± 0.85

1.68 ± 0.80

0.21 ± 0.65

0.055

0.03 ± 0.87

0.904

 Pain

2.35 ± 0.70

2.69 ± 0.71

2.44 ± 0.72

2.65 ± 0.95

0.14 ± 0.82

0.319

0.06 ± 0.85

0.831

 Dyspnea

1.48 ± 0.71

1.86 ± 0.86

1.89 ± 0.89

2.16 ± 0.90

0.42 ± 0.81

0.006

0.32 ± 0.87

0.058

 Insomnia

2.17 ± 0.92

2.20 ± 1.00

2.14 ± 0.87

2.19 ± 1.01

0.03 ± 1.08

0.944

0.10 ± 0.83

0.666

 Appetite loss

2.05 ± 0.87

2.34 ± 1.01

2.31 ± 1.06

2.35 ± 1.05

0.25 ± 1.02

0.188

0.13 ± 0.99

0.596

 Constipation

1.74 ± 0.85

1.81 ± 0.90

1.94 ± 0.83

2.26 ± 1.00

0.25 ± 0.81

0.081

0.48 ± 0.93

0.009

 Diarrhea

1.26 ± 0.58

1.49 ± 0.70

1.42 ± 0.73

1.23 ± 0.43

0.11 ± 0.92

0.505

−0.23 ± 0.50

0.039

 Financial difficulties

1.97 ± 0.86

2.15 ± 1.06

2.17 ± 0.97

2.16 ± 0.93

0.19 ± 1.04

0.231

−0.03 ± 0.60

1.000

  1. Results are presented as mean ± standard deviation
  2. EORTC QLQ-C30 European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-C30, OX-CR controlled-release oxycodone, OXN-CR controlled-release oxycodone/naloxone
  3. aPatients with available data at week 4. Scores for 22 patients in the OXN-CR group and 28 patients in the OX-CR group at week 4 were missing because these patients discontinued the study
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us